Form 4: Iteos Therapeutics COO Matthew Call Granted Stock Options

Matthew Call, Chief Operating Officer of Iteos Therapeutics, was granted stock options for 225,000 shares on March 7, 2024.

Summary

• On March 7, 2024, Matthew Call, the Chief Operating Officer of Iteos Therapeutics, Inc., was granted stock options to purchase 225,000 shares of the company's common stock.
• The exercise price of these options is $11.58 per share.
• The options vest over four years, with 25% vesting on March 7, 2025, and the remainder vesting in equal monthly installments over the subsequent 36 months, contingent upon continued service to Iteos Therapeutics.
• The options expire on March 7, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of four years with a one-year cliff (25% vesting after one year) is also typical.
• Comparing the size of the grant to similar companies and executive roles would require further analysis of Iteos Therapeutics' compensation strategy and peer group data.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the COO.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates